Scarica l'app Stockscreener
1.71
1.16%
-0.02
Dopo l'orario di chiusura:
1.71
Precedente Chiudi:
$1.73
Aprire:
$1.73
Volume 24 ore:
75,322
Relative Volume:
0.32
Capitalizzazione di mercato:
$127.42M
Reddito:
-
Utile/perdita netta:
$-19.57M
Rapporto P/E:
-0.5463
EPS:
-3.13
Flusso di cassa netto:
$-17.24M
1 W Prestazione:
-7.07%
1M Prestazione:
+6.87%
6M Prestazione:
-22.27%
1 anno Prestazione:
+26.67%
Intervallo 1D:
$1.655
$1.73
Intervallo di 1 settimana:
$1.655
$1.85
Portata 52W:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Nome
Inhibikase Therapeutics Inc
Settore
Industria
Telefono
(302) 295-3800
Indirizzo
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Confronta IKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.71 | 131.15M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
Published on: 2025-09-03 08:54:14 - Newser
Analyzing drawdowns of Inhibikase Therapeutics Inc. with statistical toolsGlobal Markets & Risk Controlled Daily Plans - Newser
Relative strength of Inhibikase Therapeutics Inc. in sector analysisWeekly Stock Report & High Return Trade Guides - Newser
Using portfolio simulators with Inhibikase Therapeutics Inc. includedCEO Change & Entry Point Strategy Guides - Newser
What earnings revisions data tells us about Inhibikase Therapeutics Inc.Quarterly Portfolio Report & Community Supported Trade Ideas - Newser
Should you hold or exit Inhibikase Therapeutics Inc. nowJuly 2025 Trends & Technical Analysis for Trade Confirmation - Newser
Will Inhibikase Therapeutics Inc. benefit from macro trendsJuly 2025 Review & Long Hold Capital Preservation Plans - Newser
Measuring Inhibikase Therapeutics Inc.’s beta against major indices2025 Trade Ideas & Daily Profit Focused Stock Screening - Newser
What is the earnings history of Inhibikase Therapeutics Inc.July 2025 Market Mood & Reliable Breakout Stock Forecasts - khodrobank.com
Does Inhibikase Therapeutics Inc. outperform in volatile markets2025 Short Interest & AI Driven Price Predictions - khodrobank.com
Is Inhibikase Therapeutics Inc. affected by consumer sentimentEarnings Growth Summary & Safe Capital Allocation Plans - khodrobank.com
What is the next catalyst for Inhibikase Therapeutics Inc.Portfolio Value Summary & Free High Accuracy Swing Entry Alerts - khodrobank.com
Is Inhibikase Therapeutics Inc. a stock for growth or value investorsJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - khodrobank.com
Using RSI to spot recovery in Inhibikase Therapeutics Inc.Earnings Recap Summary & Reliable Entry Point Trade Alerts - Newser
Can Inhibikase Therapeutics Inc. hit a new high this monthStop Loss & Momentum Based Trading Signals - Newser
Reversal indicators forming on Inhibikase Therapeutics Inc. stock2025 Institutional Moves & Community Consensus Picks - Newser
What are analysts’ price targets for Inhibikase Therapeutics Inc.2025 Geopolitical Influence & Verified Short-Term Plans - khodrobank.com
Is a relief rally coming for Inhibikase Therapeutics Inc. holdersTrade Risk Report & Daily Price Action Insights - Newser
Published on: 2025-09-01 22:20:55 - Newser
Is it time to cut losses on Inhibikase Therapeutics Inc.July 2025 PostEarnings & Weekly Watchlist for Hot Stocks - Newser
Is Inhibikase Therapeutics Inc. undervalued by DCF analysis2025 Technical Overview & Smart Swing Trading Techniques - khodrobank.com
Is Inhibikase Therapeutics Inc. forming bullish engulfing patternsWeekly Gains Summary & Fast Moving Market Watchlists - khodrobank.com
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | - openPR.com
Parkinson’s Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, - Barchart.com
Using R and stats models for Inhibikase Therapeutics Inc. forecastingQuarterly Trade Summary & Weekly High Return Stock Opportunities - Newser
Using Python tools to backtest Inhibikase Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Smart Swing Trading Techniques - Newser
Is Inhibikase Therapeutics Inc. stock a smart retirement pick2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - khodrobank.com
Inhibikase Therapeutics (NASDAQ:IKT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Published on: 2025-08-31 22:05:17 - Newser
Ranking Inhibikase Therapeutics Inc. among high performing stocks via tools2025 Big Picture & Weekly High Return Opportunities - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Live market analysis of Inhibikase Therapeutics Inc.2025 Stock Rankings & Smart Money Movement Tracker - Newser
How high can Inhibikase Therapeutics Inc. stock goJuly 2025 Action & Stepwise Trade Signal Implementation - Newser
Is Inhibikase Therapeutics Inc. affected by consumer sentiment getLinesFromResByArray error: size == 0 - sisain.net
Is Inhibikase Therapeutics Inc. Forming a Consolidation Base getLinesFromResByArray error: size == 0 - thegnnews.com
Applying Elliott Wave Theory to Inhibikase Therapeutics Inc.Market Growth Report & Technical Entry and Exit Alerts - Newser
Inhibikase Therapeutics Inc Azioni (IKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inhibikase Therapeutics Inc Azioni (IKT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):